Evidence map›Paper›PMID 22309908›Full record

ReviewNeurotoxicology2012

Industrial toxicants and Parkinson's disease.

W Michael Caudle, Thomas S Guillot, Carlos R Lazo, Gary W Miller

Abstract readReview
In one paragraph

Review in Neurotoxicology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

W Michael CaudleDepartment of Environmental Health, Rollins School of Public Health, Center for Neurodegenerative Disease, Emory University, Atlanta, GA 30322, United States. William.m.caudle@emory.edu
Thomas S Guillot
Carlos R Lazo
Gary W Miller

Funding

Graduate and Postdoctoral Training in ToxicologyT32ES012870 · NIEHS · EMORY UNIVERSITY · PI Carmen Joseph Marsit · 2004 to 2026
$9.1M
Udall Parkinson's Disease Center at Emory University: Circuitry to TherapyP50NS071669 · NINDS · EMORY UNIVERSITY · PI WICHMANN, THOMAS · 2010 to 2015
$6.8M
PROJECT 3: METABOLOMIC BIOMARKERS OF PARKINSON'S DISEASEP01ES016731 · NIEHS · EMORY UNIVERSITY · PI MILLER, GARY W · 2008 to 2012
$6.7M
Vesicular monoamine transporter 2 as a mediator of PBDE neurotoxicityR00ES017477 · NIEHS · EMORY UNIVERSITY · PI CAUDLE, WILLIAM MICHAEL · 2010 to 2012
$737k
NIEHS NIH HHS 1P01ES016731NIEHS NIH HHS 4R00ES017477NIEHS NIH HHS 5T32 ES 012870NIEHS NIH HHS P01 ES016731NIEHS NIH HHS R00 ES017477NIEHS NIH HHS T32 ES012870NINDS NIH HHS 1P50NS071669NINDS NIH HHS P50 NS071669
6 · The paper itself

Abstract

The exposure of the human population to environmental contaminants is recognized as a significant contributing factor for the development of Parkinson's disease (PD) and other forms of parkinsonism. While pesticides have repeatedly been identified as risk factors for PD, these compounds represent only a subset of environmental toxicants that we are exposed to on a regular basis. Thus, non-pesticide contaminants, such as metals, solvents, and other organohalogen compounds have also been implicated in the clinical and pathological manifestations of these movement disorders and it is these non-pesticide compounds that are the subject of this review. As toxic exposures to these classes of compounds can result in a spectrum of PD or PD-related disorders, it is imperative to appreciate shared clinico-pathological characteristics or mechanisms of action of these compounds in order to further delineate the resultant disorders as well as identify improved preventive strategies or therapeutic interventions.

Indexed as

Environmental ExposureHazardous SubstancesHumansParkinson DiseaseRisk FactorsHazardous Substances

Identifiers

PMID22309908
PMCPMC3299826

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.